Risk stratification model for foreseeing overall survival in Chinese patients with initially metastatic small-cell lung cancer

被引:0
|
作者
Fu, Rong [1 ]
Jing, Chuanqing [1 ]
Zhang, Wei [2 ]
机构
[1] Shandong Univ Tradit Chinese Med, Coll Clin Med 2, Jinan, Peoples R China
[2] Shandong Univ Tradit Chinese Med, Affiliated Hosp, Dept Resp & Crit Care Med, Jinan, Shandong, Peoples R China
关键词
Chinese patients; nomogram; overall survival; risk stratification; small-cell lung cancer; BREAST-CANCER; SEER DATABASE; NOMOGRAM; VALIDATION; BLADDER;
D O I
10.1097/MD.0000000000040145
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The study was outlined to develop and approve a nomogram and chance stratification demonstrate for foreseeing overall survival of Chinese patients with at first metastatic small-cell lung cancer (SCLC). We collected information from the Surveillance, Epidemiology, and End Results (SEER) database approximately Chinese SCLC patients with at first distant metastases between 2010 and 2015. Patients with incomplete data about the follow-up time or clinicopathological information were excluded. The included patients were randomized into the training and validation set. Univariate and multivariate Cox proportional hazard regression models were performed. By integrating the significant variables screened, a prescient nomogram and risk stratification model were developed. In addition, we collected 198 small-cell lung cancer patients with metastasis at diagnosis from the case database of the Affiliated Hospital of Shandong University of Traditional Chinese Medicine as an external validation cohort. In all, 421 patients were screened from the SEER database. Multivariate examination showed that age (P = .049), sex (P = .001), grade (P = .008), chemotherapy (P = .001), liver metastasis (P = .001), and pleural invasion (P = .012) were independent prognostic factors. The C-indicator of the nomogram to anticipate overall survival was higher than that of the eighth edition of the American Joint Committee on Cancer Tumor Node Metastasis classification system (0.75 vs 0.543; P < .001). A risk stratification model was encouraged to be created to precisely classify patients into 2 prognostic bunches. The survival rates anticipated by the nomogram appeared to have critical qualifications from the Kaplan-Meier curves in the entire SEER cohort. Calibration curves and survival predictions also showed strong accuracy and consistency in the external validation cohort. The nomogram provided a clear prognostic superiority over the traditional Tumor Node Metastasis system. It could help clinicians make individual risk predictions for initially metastatic Chinese SCLC cancer patients and give necessary treatment recommendations.
引用
收藏
页数:10
相关论文
共 50 条
  • [41] Novel nomogram predicting cancer-specific survival and overall survival in patients with primary esophageal small-cell carcinoma: A surveillance, epidemiology, and end results-based study
    Li, Jisheng
    Yu, Hejiang
    Peng, Ling
    Li, Li
    Wang, Xiangling
    Hao, Jing
    Shao, Na
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2021, 17 (03) : 630 - 637
  • [42] Time to Progression as a Surrogate Marker for Overall Survival in Patients with Advanced Non-small Cell Lung Cancer
    Hotta, Katsuyuki
    Fujiwara, Yoshiro
    Matsuo, Keitaro
    Kiura, Kutsuyuki
    Takigawa, Nagio
    Tabata, Masahira
    Tanimoto, Mitsune
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (03) : 311 - 317
  • [43] The Relationship between Prognostic Factors and Overall Survival in Small Cell Lung Cancer Patients: a Single Centre Experience
    Ustaalioglu, Bala Basak Oven
    Bilici, Ahmet
    Seker, Mesut
    Salepci, Taflan
    Ustaalioglu, Recep
    Comert, Sevda
    Mayadagli, Alpaslan
    Gumus, Mahmut
    TURKISH THORACIC JOURNAL, 2012, 13 (02) : 60 - 64
  • [44] Trends in response rate and survival in small-cell lung cancer patients between 1997 and 2017
    Lattuca-Truc, Mickael
    Timsit, Jean-Francois
    Levra, Matteo Giaj
    Ruckly, Stephane
    Villa, Julie
    Dumas, Isabelle
    Pinsolle, Julian
    Ferrer, Leonie
    Guillem, Pascale
    Moro-Sibilot, Denis
    Toffart, Anne-Claire
    LUNG CANCER, 2019, 131 : 122 - 127
  • [45] THE EFFECT OF SURGICAL TREATMENT ON SURVIVAL IN GERIATRIC PATIENTS WITH STAGE I SMALL-CELL LUNG CANCER
    Dasdemir, Gulay Ilkhan
    Celikhisar, Hakan
    Kilavuz, Asli
    TURKISH JOURNAL OF GERIATRICS-TURK GERIATRI DERGISI, 2020, 23 (04): : 455 - 462
  • [46] Anlotinib plus etoposide increases survival in patients with small-cell lung cancer after chemoradiotherapy
    Gao, Lizhen
    Wang, Junqing
    Chen, Junlin
    Zhang, Xuelin
    Zhang, Manman
    Wang, Suling
    Zhao, Chen
    JOURNAL OF RADIATION RESEARCH AND APPLIED SCIENCES, 2022, 15 (04)
  • [47] Prognostic indicators of survival in patients with small-cell lung cancer at a tertiary care center in Lebanon
    Tfayli, Arafat
    Atwi, Hanine
    Naji, Amal
    Assaad, Majd Al
    Assi, Sahar
    Hazimeh, Maya
    SAGE OPEN MEDICINE, 2021, 9
  • [48] Autoimmunity to SOX2, clinical phenotype and survival in patients with small-cell lung cancer
    Maddison, Paul
    Thorpe, Alison
    Silcocks, Paul
    Robertson, John F. R.
    Chapman, Caroline J.
    LUNG CANCER, 2010, 70 (03) : 335 - 339
  • [49] Nomogram model for predicting cause-specific mortality in patients with stage I small-cell lung cancer: a competing risk analysis
    Li, Jianjie
    Zheng, Qiwen
    Zhao, Xinghui
    Zhao, Jun
    An, Tongtong
    Wu, Meina
    Wang, Yuyan
    Zhuo, Minglei
    Zhong, Jia
    Yang, Xue
    Jia, Bo
    Chen, Hanxiao
    Dong, Zhi
    Wang, Jingjing
    Chi, Yujia
    Zhai, Xiaoyu
    Wang, Ziping
    BMC CANCER, 2020, 20 (01)
  • [50] Nomogram model for predicting cause-specific mortality in patients with stage I small-cell lung cancer: a competing risk analysis
    Jianjie Li
    Qiwen Zheng
    Xinghui Zhao
    Jun Zhao
    Tongtong An
    Meina Wu
    Yuyan Wang
    Minglei Zhuo
    Jia Zhong
    Xue Yang
    Bo Jia
    Hanxiao Chen
    Zhi Dong
    Jingjing Wang
    Yujia Chi
    Xiaoyu Zhai
    Ziping Wang
    BMC Cancer, 20